Immatics at AACR Annual Meeting 2018 (Apr 14-18) in Chicago, IL

| News

Immatics is a part of the #AACR18 Annual Meeting, April 14-18! Under this year’s topic „Driving Innovation Cancer Science to Patient Care" we will be presenting various insights and our latest news on cancer research and immunotherapy. Come and join our experts from Immatics US and Germany – we can’t wait to meet you there: 

 

“IMA-Detect: Mass spectrometry guided development and clinical application of a companion diagnostic for adoptive cellular therapy against tumor associated HLA peptides“ (poster #662/30)

April 15th, 1-5pm

Session PO.CL01.01 - Molecular Diagnostics 1: Cytogenetics, Clinical Molecular Genetics, and Clinical Imaging

Presenter: Arun Satelli (Associate Director, Discovery)

 

“Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands“ (poster #2789/22)

April 16th, 1-5pm

Session PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2

Presenter: Sebastian Bunk (Director Immunology, TCR Engineering & Bispecifics)

 

“Phase I adoptive cellular therapy trial with actively personalized, multi-targeted CD8+ T-cells in patients with relapsed and/or refractory solid cancers“ (poster #CT127/10)

April 17th, 8am-12pm

Session PO.CT04 - Phase I Trials in Progress

Presenter: Hong Ma (Sr. Director, Clinical Development)

 

“ACTallo: A novel approach using gamma-delta T cells to allogeneic cellular therapy to treat cancer” (poster #3588/26)

April 17th, 8am-12pm

Session PO.CL06.03 - Adoptive Cell Therapy 3

Presenter: Melinda Mata (Scientist, Product Science)

 

 

Press Contact

Dr Nikola Wiegeler

Press contact,
Immatics Biotechnologies GmbH

+49 7071 5397-0

Go back